care of severe sepsis. METHODS: Observational prospective before and after study
PIN57 A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCV13) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK
Patel R 1 , Stoykova B 2 , Lloyd AC 1 , Willingham J 2 , Hollingsworth R 2 1 IMS Health, London, UK, 2 Wyeth, Maidenhead, Berkshire, UK OBJECTIVES: A 7-valent pneumococcal conjugate vaccine (PCV7, Prevenar*) is currently recommended for childhood vaccination in the UK. A 10-valent vaccine (PCV10, Synflorix, GSK) is licensed and a 13-valent vaccine (PCV13, Wyeth) is currently being reviewed by regulatory authorities. This study estimated the cost effectiveness of PCV13 and PCV10 compared to PCV7 for childhood vaccination in the UK. METHODS: A steady state, static cohort model was constructed comparing the incremental benefit of PCV13 compared to PCV7 and PCV10 compared to PCV7 for vaccination of the entire birth cohort. In children, the model considered the incidence and subsequent costs of four disease states: pneumococcal meningitis; pneumococcal bacteraemia; all cause pneumonia and acute otitis media (AOM). In adults the model considered invasive pneumococcal disease (IPD) and all cause pneumonia, exploring the potential impact of herd immunity. Sensitivity analyses were conducted on incidence, mortality rates, vaccine efficacy, serotype coverage and costs, discount rate, uptake and non-vaccine serotype prevalence. RESULTS: The model estimated that, in addition to PCV7, PCV13 (PCV10) would annually reduce the incidence of IPD by 888 (573) cases, prevent 23 (16) deaths, increase the number of life years gained by 509 (343), increase QALYs gained by 611 (375) and reduce medical costs by £5.2m (£3.3m). The benefits of the new vaccines are sensitive to efficacy and the magnitude and pattern of herd immunity that emerges. CONCLUSIONS: Our analysis found that PCV13 vaccination in the UK will be more effective than PCV10 in reducing the burden of pneumococcal disease when compared to PCV7 and will further reduce cost. Final cost-effectiveness will depend on the emergence of herd immunity benefits in the UK, the impact on AOM and pneumonia, the vaccination schedule deployed and price of PCV13 and PCV10.
PIN58 COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENT-EXPERIENCED HIV-1-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS
Moeremans K 1 , Hjelmgren J 2 , Martin SC 3 1 IMS HEOR, Brussels, Belgium, 2 Janssen-Cilag AB, Sollentuna, Sweden, 3 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium OBJECTIVES: To determine whether, from the Swedish health care payer perspective etravirine is cost-effective when added to a standard highly active antiretroviral treatment (HAART) in multi-drug resistant HIV-1 infected adults. METHODS: Etravirine added to a standard regimen including darunavir/r, an optimized background regimen (OBR) of nucleoside reverse transcriptase inhibitors (NRTIs) and optionally enfuvirtide was compared to the same standard regimen alone. The target population consisted of HIV-1-infected pretreated patients with resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and 3 protease inhibitor (PI) mutations. Cost-effectiveness, expressed as cost per quality-adjusted life year (QALY) gained, was calculated using a lifetime Markov model. The model predicted patient flow through six health states representing CD4 T-cell count ranges ( 500, 351-500, 201-350, 101-200 , 51-100 and 0-50 cells/mm3), and one absorbing 'death' state. After treatAfter treatment failure, a switch to a raltegravir regimen was assumed. Transition probabilities raltegravir regimen was assumed. Transition probabilities . Transition probabilities probabilities describing patient flow through the model were obtained from immunologic response rates per virologic response category observed in the DUET trials for etravirine and placebo and reported in phase III trials for raltegravir. All-cause mortality was All-cause mortality was obtained from Swedish statistics. HIV-related mortality, utilities and non-ARV costs associated with each CD4 T-cell count range were obtained from literature. AntiretAntiretroviral (ARV) drug use reflected that observed in the clinical trials. Outcomes and ARV) drug use reflected that observed in the clinical trials. Outcomes and and costs expressed in 2008 Swedish Kronor (SEK) were discounted at 3%. The impact of parameter uncertainty was explored in one-way as well as probabilistic sensitivity analysis. Variability analyses explored different model assumptions. RESULTS: The analysis predicted a gain in discounted QALYs of 0.461 and an incremental cost per QALY of SEK362,583, ranging from 240,074SEK/QALY to 474,935SEK/QALY in sensitivity and variability analyses. CONCLUSIONS: The results suggest etravirine to be cost-effective in Sweden when added to a standard multi-drug regimen in pretreated HIV patients with evidence of NNRTI and PI resistance.
PIN59 POTENTIAL ECONOMIC IMPACT OF OUTPATIENT CARBAPENEM TREATMENT FOR BACTERAEMIA CAUSED BY ESBL-PRODUCING BACTERIA IN HONG KONG-A DECISION ANALYSIS
You JH, So M, So Y, Ip M, Lee NL The Chinese University of Hong Kong, Shatin, N.T, Hong Kong OBJECTIVES: Outpatient parenteral antimicrobial therapy (OPAT) with carbapenem for bacteraemia caused by extended-spectrum beta-lactamase (ESBL)-producing bacteria may potentially be cost-saving. Yet in Hong Kong, China and many southeast Asia regions, patients requiring intravenous antimicrobial therapy are usually treated in an in-patient setting. In the present study, we analyzed the cost of inpatient versus outpatient carbapenem treatment for ESBL bacteraemia. METHODS: Economic outcomes of two antimicrobial strategies were simulated by a decision tree: 1) inpatient carbapenem treatment; 2) outpatient group (initially inpatient carbapenem treatment followed by ertapenem OPAT). Clinical inputs were estimated from literature and cost analysis was conducted from Hong Kong public health care provider's perspective. Robustness of model was examined by sensitivity analysis. RESULTS: The results showed that outpatient group (US$12,008) was less costly than the inpatient group (US$15,446) (USD1 HKD7.8) by 22% in base-case analysis. The model was robust to variation of all variables in one-way sensitivity analysis. In Monte Carlo stimulations, cost of outpatient group (US$13,153 2,064) was significantly lower than the 2,064) was significantly lower than the inpatient group (US$15,650 1,602) 98.6% of the time by a mean difference of 1,602) 98.6% of the time by a mean difference of US$2,497 (95% CI US$2,469-2,525) (p 0.0001). CONCLUSIONS: Initial inpatient carbapenem treatment followed by OPAT appears to be less costly than an inpatient treatment course for ESBL bacteraemia from the perspective of Hong Kong public health care providers. 
